Soluble Therapeutics Inc. has a second cash infusion that will help the company continue its work in protein-based pharmaceuticals as well as pursue two major research collaborations with global and U.S. partners.

The company, which is based in Birmingham’s Innovation Depot incubator, said Targeted Technology Fund II in San Antonio provided the undisclosed amount of funding. The investment comes at a year after Soluble received a $1 million grant from the National Institutes of Health.

Soluble said in a release the new funding will be used towards the company’s new research collaborations with a global pharmaceutical contract manufacturing organization and one with a large U.S.-based pharmaceutical company, that could lead to exclusive licensing deals for Soluble’s HSC technology.

The technology has to do with formulations to enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings the transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics.

“This funding represents a vote of confidence in the work that Soluble Therapeutics is doing and will allow us to continue expanding upon our initial success,” Joseph Garner, chief executive of Soluble, said in a release. “We are very excited about the research collaborations kicking off in 2014 and further demonstrating the value of the HSC technology in the marketplace.” back

StemBioSys, a San Antonio-based bioscience startup, is looking to raise $8 million in new Series A investor funding. The company has already secured more

Medical-device firm Xenex attracts big Investment. When Rackspace Hosting co-founder Morris Miller more

Xenex CEO expects 2013 revenues to be north of $20 Million. Xenex Disinfection Services’ Morris Miller expects more

Xenex Secures $11.3 Million in Funding; Superbug Zapping Robot Enhances Patient Safety by Eliminating Pathogens that Cause Hospital Infections more

DNAtrix Announces Treatment of First Patient in Study with Recurrent Glioblastoma Using DNX-2401 and Temozolomide more

Medical Innovation iTClamp Hemorrhage Control System Used for First Time in United States more

BiO2 Medical Executes Full Commercialization in the United Kingdom Partnering with United Drug Medical (UDM) as an Exclusive Distributor for the Angel® Catheter more

DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus more

ArthroCare Announces Acquisition of ENTrigue Surgical, Inc more

Vidacare projects big revenue spike for 2013 more

BiO2 Medical's IDE Application for the Angel(TM) Catheter Receives FDA Approval more

Medical Device Firm iTraumaCareTM Receives FDA 510(k) Clearance for iTClampTM Hemorrhage Control System more

BiO2 Medical's IDE Application for the Angel(TM) Catheter Receives FDA Approval more

Woman, 80, gets new blood clot prevention device more

BioDtech, Inc. Issued New United States Patent more

Successful Completion of Santalis Pharmaceuticals Initial Clinical Trials more